Pacira Biosciences Inc expected to post earnings of 70 cents a share - Earnings Preview

Pacira Biosciences

30/10/2024 13:29

* Pacira Biosciences Inc  PCRX.OQ   PCRX.O  is expected
to show a
rise in quarterly revenue when it reports  results on November 1
(estimated) for the period ending September 30 2024
    * The Tampa Florida-based  company is expected to report a
3.5% increase in revenue to $169.672 million from $163.93
million a year ago, according to the mean estimate from 9
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Pacira Biosciences Inc
is for
earnings of 70 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 4
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Pacira
Biosciences Inc is 18.00​, above​ its last closing price
of $17.18. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  0.71        0.70       0.89      Beat    27.3
 Mar. 31 2024  0.61        0.62       0.62      Met     -0.6
 Jan. 1 0001   0.88        0.88       0.89      Beat    0.7​
 Sep. 30 2023  0.77        0.78       0.72      Missed  -8.2
 ​​Jun.        0.77        0.76       0.78      Beat    2.9
 30 2023                                                
 Mar. 31 2023  0.62        0.62       0.53      Missed  -14.1​
 Dec. 31 2022  0.82        0.83       0.80      Missed  -3.6
 Jan. 1 0001   0.71        0.76       0.64      Missed  -16.2
 This summary was machine generated October 30 at 13:29 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)